Verteporfin (CL 318952)

Catalog No.S1786 Synonyms: Visudyne

For research use only.

Verteporfin (CL 318952, Visudyne) is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.

Verteporfin (CL 318952) Chemical Structure

CAS No. 129497-78-5

Selleck's Verteporfin (CL 318952) has been cited by 109 publications

Purity & Quality Control

Choose Selective VDA Inhibitors

Other VDA Products

Biological Activity

Description Verteporfin (CL 318952, Visudyne) is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.
Targets
VDA [1]
(Endothelial cells)
YAP/TEAD interaction [3]
In vitro

Verteporfin is about four times more efficient in absorbing light at wavelengths that penetrate tissues best (i.e., around 700 nm) and thus provides a much higher cytotoxic effect than hematoporphyrin (10 times more in human adherent cell lines). Verteporfin is lipophilic and is more readily taken up by malignant or activated cells, compared with normal or resting cells. Verteporfin binds with LDL to form a complex, which is then taken up into proliferating cells (e.g., neovascular endothelial cells) probably via LDL receptors and endocytosis. Verteporfin therapy achieves complete angiographic occlusion of the neovascular compartment by thrombosis of vascular channels, following selective endothelial damage. Verteporfin therapy selectively induces reproducible and isolated choriocapillary occlusion without alteration of overlying photoreceptors or ganglion cells, as shown by light and electron microscopy. [1] Verteporfin conbined with light rapidly exhibits apoptotic changes reflected by caspase-3 and caspase-9 activation and PARP cleavage in HL-60 cells, changes that are blocked by the general caspase inhibitor ZVAD.fmk. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HL-60 MX7GeY5kfGmxbjDhd5NigQ>? NEDWVZd,OTByIH7nM41N NIjVR|RFVVOR NF7OR|ZqdmO{ZXHz[ZMhTE6DIH\yZYdu\W62YYTpc44hdGW4ZXzz M2rOPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyNkC3O|ExLz5zME[wO|cyODxxYU6=
HL-60 MmPjZ5l1d3SxeHnjbZR6KGG|c3H5 NV3jepNNhjFyMDDu[{9uVA>? MoLxSG1UVw>? NFzr[ItqdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= Mlz2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB4MEe3NVAoRjFyNkC3O|ExRC:jPh?=
Jurkat MUHBdI9xfG:|aYOgZZN{[Xl? MkO4glI5OCCwTR?= MX\EUXNQ M3exfIlv\HWlZYOgZUBD[2xvMj3k[ZBmdmSnboSgZZBweHSxc3nz NXXG[Hk5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGyOFU1OTVpPkGxNlQ2PDF3PD;hQi=>
RIF-1 NVriXIN4TnWwY4Tpc44h[XO|YYm= MoezNUDPxGdxbXy= NYm1O3VZTE2VTx?= NHXvOIVl\WO{ZXHz[ZMhd3i7Z3XuJINwdnO3bYD0bY9v M3PKeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{NkG1O|E5Lz5zMk[xOVcyQDxxYU6=
RIF-1 NGXofYZkgXSxdH;4bYNqfHliYYPzZZk> MkG5NUDPxGdxbXy= NWr6[FVpTE2VTx?= M{Cy[IRm[3KnYYPlJJRwKDJyINMxJFUmKGOnbHygd5Vzfmm4YXy= MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjZzNUexPEc,OTJ4MUW3NVg9N2F-
SVEC4-10 NFu4dIZHfW6ldHnvckBie3OjeR?= MVWyNFAhdmdxbXy= MoXQSG1UVw>? M3;pUIlv\HWlZYOgcYlkem:2dXL1cIUh\GWyb3z5cYVzcXqjdHnvci=> NXHZbHo3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0OlcyODZpPkG2OFY4OTB4PD;hQi=>
SVEC4-10 MV;GeY5kfGmxbjDhd5NigQ>? MXKyNFAhdmdxbXy= NIPmWJNFVVOR NX70cHhDcW6mdXPld{B{fHKnc4OgZYN1cW5iZnni[ZIh\m:{bXH0bY9v M2jCTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NE[3NVA3Lz5zNkS2O|ExPjxxYU6=
ARPE-19 MUPjfZRwfG:6aXPpeJkh[XO|YYm= Mlf2glAvOSEQvHevcYw> NEDuRZZFVVOR MX\zbI94eyCjIHTvd4Uu\GWyZX7k[Y51KHSxeHnjbZR6 MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjl6N{mwOUc,OTZ7OEe5NFU9N2F-
ARPE-19 MY\GeY5kfGmxbjDhd5NigQ>? MUiwMlAyKM7:Zz;tcC=> MYLEUXNQ NGjXR3RqdmO{ZXHz[ZMhXkWJRjDhcoQhemWmdXPld{BRTUSIIHX4dJJme3Orb36= M4fTSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUi3PVA2Lz5zNkm4O|kxPTxxYU6=
Y-79 M4DC[Gdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYL+NUDPxGdxbXy= NEf1NWJFVVOR Mlzt[IVkemWjc3XzJJJmfGmwb3LsZZN1d22jIHPlcIwheHKxbHnm[ZJifGmxbh?= NIO1Ooo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW3PVc3PCd-MUi1O|k4PjR:L3G+
WERI-Rb1 M4fGOGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NUm2dlVMhjFizsznM41t MlTySG1UVw>? M4fpc4Rm[3KnYYPld{Bz\XSrbn;icIF{fG:vYTDj[YxtKHC{b3zp[oVz[XSrb36= NWPDW3RURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1O|k4PjRpPkG4OVc6PzZ2PD;hQi=>
RB247C3 MnnsS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Ml:zglEh|rypL33s M{CzSGROW09? NEnB[|Vl\WO{ZXHz[ZMhemW2aX7vZoxie3SxbXGgZ4VtdCCycn;sbYZmemG2aX;u NHzoO2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW3PVc3PCd-MUi1O|k4PjR:L3G+
RB355 M1uzSGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NI\abop,OSEQvHevcYw> M{i5d2ROW09? M4\iNIRm[3KnYYPld{Bz\XSrbn;icIF{fG:vYTDj[YxtKHC{b3zp[oVz[XSrb36= NVfQfYNIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1O|k4PjRpPkG4OVc6PzZ2PD;hQi=>
RB383 MlLiS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MV7+NUDPxGdxbXy= NX72cZNiTE2VTx?= NXHsbGNE\GWlcnXhd4V{KHKndHnuc4Jt[XO2b33hJINmdGxicILvcIln\XKjdHnvci=> NITDUIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW3PVc3PCd-MUi1O|k4PjR:L3G+
hFibro MYLjfZRwfG:6aXPpeJkh[XO|YYm= NVXtSHVwOC53INM1[{9udA>? Mne1SG1UVw>? NEDHSWdl\WO{ZXHz[ZMhfmmjYnnsbZR6KGK7IEi2MFUm M4LqT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NESxNVE1Lz5{M{S0NVEyPDxxYU6=
pTMC NUTlfGd5[3m2b4TvfIlkcXS7IHHzd4F6 M1n1N|AvPSEEtXevcYw> NUnJOpp{TE2VTx?= NXfROWZZ\GWlcnXhd4V{KH[rYXLpcIl1gSCkeTC5Nk46LQ>? NVHWOG5WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0OFEyOTRpPkKzOFQyOTF2PD;hQi=>
hTMC NH\FPW9kgXSxdH;4bYNqfHliYYPzZZk> MWqwMlUhyrWpL33s MnTCSG1UVw>? NHrQXVRl\WO{ZXHz[ZMhfmmjYnnsbZR6KGK7IEi4Mlkm NF\zN209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S0NVEyPCd-MkO0OFEyOTR:L3G+
ARPE-19 NYfIXYEz[3m2b4TvfIlkcXS7IHHzd4F6 MXGwMlUhyrWpL33s MmnaSG1UVw>? MUHk[YNz\WG|ZYOgeoli[mmuaYT5JIJ6KDV3LkWl MoDNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2NEGxNVQoRjJ|NESxNVE1RC:jPh?=
Panc-1 MkDWS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHfMenEyOCEQvF2= M2TaT2ROW09? NWTmV3pzcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v NFftdZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC2PVA3QSd-MkSwOlkxPjl:L3G+
MIA PaCa-2 NFfIdIZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MXWxNEDPxE1? Mkm5SG1UVw>? NUH5TZRocW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v NF;Nc|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC2PVA3QSd-MkSwOlkxPjl:L3G+
BxPC-3 MXfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NHPiRpgyOCEQvF2= NHnmUGVFVVOR M1znfIlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBkd22ybHX0[Yx6 M4\3dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2ME[5NFY6Lz5{NEC2PVA3QTxxYU6=
SU86.86 MmnHS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFXieIMyOCEQvF2= Mm[xSG1UVw>? M1HmWolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBkd22ybHX0[Yx6 Ml;rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNkmwOlkoRjJ2ME[5NFY6RC:jPh?=
MCF-7 M3G1PGF2fG:yaHHnfUBie3OjeR?= MnTBNVAh|ryP M2PMc2ROW09? MmjGbY5pcWKrdIOg[4Vu[2m2YXLpcoUucW6mdXPl[EBifXSxcHjh[5k> MmH1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNkmwOlkoRjJ2ME[5NFY6RC:jPh?=
WERI M4\Vbmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M3PJNJ4yOCEQvHevcYw> M3THb2ROW09? NWOyOGFGcW6qaXLpeJMh\3Kxd4ToJI9nKHKndHnuc4Jt[XO2b33hJINmdGy| MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|N{G0Nkc,OjR6M{exOFI9N2F-
WERI NYi0[4RLTnWwY4Tpc44h[XO|YYm= NXTQVYlChjFyIN88[{9udA>? MVPEUXNQ NVzWTWxt[myxY3vzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25? NEXxVoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizO|E1Oid-MkS4N|cyPDJ:L3G+
Y-79 M1TXbWZ2dmO2aX;uJIF{e2G7 NF\6[lV,OTBizsznM41t NFrsfGpFVVOR NFnIR25jdG:la4OgZ4VtdCCleXPs[UBxem:pcnXzd4lwdg>? NVTXWlkyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|cyPDJpPkK0PFM4OTR{PD;hQi=>
Y-79 MWDGeY5kfGmxbjDhd5NigQ>? MlLwglExKM7:Zz;tcC=> NHfOZ4NFVVOR NHLkOVli\m[nY4TzJHlCWC2WRVHEJJBzd3SxLX;uZ49o\W6nIIDheIh4[Xl? NEjoe4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizO|E1Oid-MkS4N|cyPDJ:L3G+
Y-79 NVvTeXhVTnWwY4Tpc44h[XO|YYm= MlLuglExKM7:Zz;tcC=> MXrEUXNQ NYq1dlI3\G:5bj3y[Yd2dGG2ZYOgdIx2emmyb4TlcoN6KG2jcnvldkBQS1RvNB?= M2fPbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEO3NVQzLz5{NEizO|E1OjxxYU6=
Phototoxicity assay MlKyRlE3TjFy NFu4bGkzPCCqcoO= MlfKTWM2OCB;IEGuNFch|ryP Mo\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{[zPFkoRjJ5MUO2N|g6RC:jPh?=
Phototoxicity assay NYrJW2tOSjF4RkGw MWCyOEBpenN? MnO1TWM2OCB;IEGuNkDPxE1? M17SVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUO2N|g6Lz5{N{GzOlM5QTxxYU6=
Phototoxicity assay MVTBN|c2 NFrwPXkzPCCqcoO= NFSzTYlKSzVyIE2gNk4xPiEQvF2= MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF|NkO4PUc,OjdzM{[zPFk9N2F-
Dark toxicity assay NXTxb3B[SjF4RkGw M3z2N|Q5KGi{cx?= NUWw[2pRUUN3MDC9JFI1Njl{IN88US=> MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF|NkO4PUc,OjdzM{[zPFk9N2F-
Dark toxicity assay MVXCNVZHOTB? NXfZflNoPDhiaILz NHjoU4hKSzVyIE2gNlUvODNizszN Mln1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{[zPFkoRjJ5MUO2N|g6RC:jPh?=
Dark toxicity assay MoPURVM4PQ>? NVXzPIdbPDhiaILz Moi0TWM2OCB;IEO2MlM{KM7:TR?= MlnvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{[zPFkoRjJ5MUO2N|g6RC:jPh?=
qHTS assay NXrXbZBmXEN|Mh?= NY\WcJg2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGTDN|Ih[2WubIO= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
qHTS assay MW\VMVIhV1N? NUPZV|BKeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGWtNkBQWyClZXzsdy=> MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
qHTS assay MX3BOlc{ M4O1fZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| Mo\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay NVO5ZYZnTEGRWR?= NXzCcpE1eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO= M1fmRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay MorHV4Fwey1{ NWW2W45GeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=> MmDwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay NGnZc2xDXC1|Nx?= NWi5WFJGeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
qHTS assay NIDHb4hTTA>? MYrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM> Ml60QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay MnLSV2suVi2VSB?= MmTYdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= MnT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay MVvCWE0yOg>? M2ixPJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= NWDTOGFORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay MWHNS{A3OyBqNj3US{BTMQ>? MkDSdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| NFjkNWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
qHTS assay MYrPTHMuPTB? Mkn1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= NXf2SGJ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay MojJVog1OQ>? NF7Wd5NyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?= M{WxR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay NVLa[VF1W0pvR1LNNi=> M4S4RZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz NHO3c4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
qHTS assay MVfTT{1PNU2F M4e4bZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz M321TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay NXX0fm5nVEGQLUW= MlrydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy| NHPaXZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Antitumor assay NV\HN5lJSjF4RkGw NWXJcY9pOiCvZz;r[y=> NYXZT41UOiCqcoO= NIP6d4RCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBDOT[IMUCgZ4VtdHNiaX3wcIFvfGWmIHnuJGM2P0KOL{[gcY92e2ViYYPz[ZN{\WRiYYOgeJVud3JiZ4Lve5RpKGmwaHnibZRqd25iYYSgNkBu\y:tZzygbZYh[WSvaX7pd5RmemWmIH\vdkAzKGi{czDmc4xtd3enZDDifUBqenKjZHnheIlwdiC5aYToJIxie2W{IHH0JFE2OCCML3PtK|Ih\m:{IEGwJI1qdnN? NF3CVWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzOlM5QSd-MkexN|Y{QDl:L3G+
Assay
Methods Test Index PMID
Western blot p-S6(S240/244) / p-4EBP1(S65) ; c-Myc / Bcl-2 ; ECAD / Vimentin / Sox2 / CD44 / CD133 ; beta-catenin 28202507 29416644 30467925
Growth inhibition assay Cell viability 28042502
Immunofluorescence YAP1 ; Calreticulin ; p-YAP(Y357) 30254296 28404908
In vivo Verteporfin can be used for angiographic visualization of choroidal vessels and CNV, which demonstrates that the photosensitizer accumulates rapidly in experimental CNV in monkeys. Verteporfin accumulates rapidly in the established vasculature of the choroid, RPE, and photoreceptors of rabbit eyes. Verteporfin reaches maximal tissue levels within 3 hours of intravenous injection, followed by a rapid decline within 24 hours in mice. Verteporfin is metabolized to a less active form in vivo and is cleared very rapidly, predominantly in the feces and a very small proportion excreted in urine. Verteporfin therapy effectively and selectively prevents fluorescein dye leakage from experimentally induced CNV in monkeys. [1]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 718.79
Formula

C41H42N4O8

CAS No. 129497-78-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles COC(=O)CCC1=C(C)C2=CC3=NC(=CC4=C(C)C(=C([NH]4)C=C5N=C(C=C1[NH]2)C(=C5C)CCC(O)=O)C=C)C6=CC=C(C(C(=O)OC)C36C)C(=O)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04590664 Recruiting Drug: Verteporfin Glioblastoma|Recurrent Glioblastoma Emory University|National Cancer Institute (NCI) January 15 2021 Phase 1|Phase 2
NCT03797547 Active not recruiting Other: AFLIBERCEPT Myopic Choroidal Neovascularisation Poitiers University Hospital June 22 2018 --
NCT01846273 Completed Drug: Ranibizumab|Drug: Verteporfin PDT|Drug: Sham PDT Age-related Macular Degeneration|Polypoidal Choroidal Vasculopathy Novartis Pharmaceuticals|Novartis August 7 2013 Phase 4
NCT00423189 Terminated Drug: Ranibizumab (Lucentis)|Drug: 0.5mg ranibizumab Age-Related Macular Degeneration David M. Brown M.D.|Novartis Pharmaceuticals|Greater Houston Retina Research January 2007 Phase 4
NCT00403442 Terminated Device: Verteporfin Therapy/ Drug: Bevacizumab Macular Degeneration Vitreous -Retina- Macula Consultants of New York|QLT Inc. September 2006 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Verteporfin (CL 318952) | Verteporfin (CL 318952) ic50 | Verteporfin (CL 318952) price | Verteporfin (CL 318952) cost | Verteporfin (CL 318952) solubility dmso | Verteporfin (CL 318952) purchase | Verteporfin (CL 318952) manufacturer | Verteporfin (CL 318952) research buy | Verteporfin (CL 318952) order | Verteporfin (CL 318952) mouse | Verteporfin (CL 318952) chemical structure | Verteporfin (CL 318952) mw | Verteporfin (CL 318952) molecular weight | Verteporfin (CL 318952) datasheet | Verteporfin (CL 318952) supplier | Verteporfin (CL 318952) in vitro | Verteporfin (CL 318952) cell line | Verteporfin (CL 318952) concentration | Verteporfin (CL 318952) nmr